Diligence memo · auto-generated · as of July 2, 2026
Derma Sciences, Inc.
Derma Sciences, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Derma Sciences, Inc. operates in Pharmaceuticals, based in Princeton.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Derma Sciences, Inc. has raised $29M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $29M on 2011-06-20.
Most recent recorded round closed around 2011-06-20.
Valuation (modeled)modeled
Provath models Derma Sciences, Inc. at approximately $989M (range $61M–$3.8B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.34× the median modeled value of Series B Pharmaceuticals companies in 2010–2012 (47 peers) — value vs value, same stage and era. Within the normal band (134% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 15.0 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 73% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 89% of those peers.
Closest niche peers: Celator Pharmaceuticals Inc, Kythera Biopharmaceuticals Inc, Palatin Technologies Inc, Pernix Therapeutics Holdings, Inc., CEBIX Inc.
Peoplefiled
13 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.